C4 Therapeutics, Inc.
CCCCHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframePart of the healthcare sector, C4 Therapeutics, Inc. (CCCC) is listed under Biotechnology. Valued at $483.2M, CCCC is a small-cap name in its sector. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Market Cap
$483.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-3.78
EPS (TTM)
$-1.10
EPS (Fwd)
$-1.16
ROE
-48.4%
ROA
-19.9%
Cash
$235.7M
Total Debt
$58.4M
Free CF
-$50.5M
52W Change
228.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $235.7M in cash comfortably exceeding the $58.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$50.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -48.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $31.1M to $35.9M.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CCCC.